Jun 30, 2024, 14:51
Sergio Cifuentes: Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X about a recent paper by Myriam Chalabi et al. titled “Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer” published in The New England Journal of Medicine:
Sergio Cifuentes commented on X sharing this paper:
“Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer: 98% timely surgery, 95% major pathological response, 0 recurrences in 26 months.”
Source: Sergio Cifuentes/X
Anja Van Lent
Brechtje Grotenhuis
cancer
Cecile Grootscholten
CENEIT México
dMMR
dMMR colon cancer
Eduard Hendriks
Emile Voest
Geerard Beets
Inge Huibregtse
ipilimumab
Jacobus Burger
John Haanen
José van den Berg
June Rogers Colon Cancer Research Fund.
Koert Kuhlmann
Lodewyk Wessels
Monique Van Leerdam
Myriam Chalabi
Neoadjuvant nivolumab plus ipilimumab
Nikè Büller
nivolumab
OncoDaily
Oncology
Pedro Batista Tan
Petur Snaebjornsson
Regina Beets-Tan
Sara Balduzzi
Sergio Cifuentes
Simone Dokter
Steven Oosterling
Tjeerd Aukema
Ton Schumacher
Yara Verschoor
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023